Real-world effectiveness of casirivimab plus indevimab in a dedicated ambulatory unit created for patients with early COVID-19 during a massive delta variant wave.
Ambulatory care
COVID-19
Delta variant
Monoclonal antibodies
Real life
Journal
European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology
ISSN: 1435-4373
Titre abrégé: Eur J Clin Microbiol Infect Dis
Pays: Germany
ID NLM: 8804297
Informations de publication
Date de publication:
Aug 2022
Aug 2022
Historique:
received:
13
01
2022
accepted:
18
07
2022
pubmed:
28
7
2022
medline:
5
8
2022
entrez:
27
7
2022
Statut:
ppublish
Résumé
Only limited real-life data are available on the effects of neutralizing monoclonal antibodies in high-risk patients who have early COVID-19 and do not require supplemental oxygen. We prospectively studied 217 patients infected by the delta variant who received casirivimab plus indevimab in a dedicated ambulatory unit created during our 4th COVID wave. Mean age was 64 years, 94% had at least one comorbidity, and mean duration of symptoms was 2.9 days. Oxygen requirement, hospitalization, and mortality rates were 10, 6, and 2.8%, respectively. These results suggest benefits of early administration of neutralizing antibodies in high-risk patients infected with the delta variant.
Identifiants
pubmed: 35896762
doi: 10.1007/s10096-022-04474-9
pii: 10.1007/s10096-022-04474-9
pmc: PMC9330989
doi:
Substances chimiques
Antibodies, Monoclonal, Humanized
0
casirivimab
J0FI6WE1QN
Oxygen
S88TT14065
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
1145-1149Informations de copyright
© 2022. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature.
Références
N Engl J Med. 2021 Dec 2;385(23):e81
pubmed: 34587383
JAMA. 2020 Jul 14;324(2):131-132
pubmed: 32539093
MMWR Morb Mortal Wkly Rep. 2021 Oct 29;70(43):1513-1519
pubmed: 34710076
Nature. 2021 Aug;596(7871):276-280
pubmed: 34237773
N Engl J Med. 2021 Jan 21;384(3):238-251
pubmed: 33332778
Transplantation. 2021 Jan 1;105(1):37-55
pubmed: 33148977
Clin Infect Dis. 2022 Mar 23;74(6):1063-1069
pubmed: 34166513
N Engl J Med. 2021 Oct 7;385(15):1382-1392
pubmed: 34260849
J Infect Dis. 2021 Oct 28;224(8):1278-1286
pubmed: 34279629
N Engl J Med. 2021 Jan 21;384(3):229-237
pubmed: 33113295